AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the sale, the senior vice president now owns 28,336 shares in the company, valued at approximately $566,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Julie Krop also recently made the following trade(s):

  • On Monday, May 1st, Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock. The shares were sold at an average price of $24.45, for a total value of $46,234.95.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) traded up 0.50% on Friday, reaching $20.05. The company had a trading volume of 698,030 shares. AMAG Pharmaceuticals, Inc. has a 52 week low of $16.00 and a 52 week high of $36.83. The firm’s market capitalization is $702.65 million. The stock’s 50 day moving average is $18.02 and its 200 day moving average is $23.21.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. The firm had revenue of $139.47 million during the quarter, compared to analysts’ expectations of $150.32 million. During the same period last year, the company earned ($0.22) earnings per share. The business’s revenue for the quarter was up 27.6% compared to the same quarter last year. On average, equities analysts anticipate that AMAG Pharmaceuticals, Inc. will post $5.40 EPS for the current year.

TRADEMARK VIOLATION WARNING: “AMAG Pharmaceuticals, Inc. (AMAG) SVP Sells $98,760.00 in Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/14/amag-pharmaceuticals-inc-amag-svp-sells-98760-00-in-stock.html.

A number of hedge funds have recently bought and sold shares of AMAG. Clark Estates Inc. NY raised its stake in AMAG Pharmaceuticals by 16.5% in the first quarter. Clark Estates Inc. NY now owns 120,100 shares of the specialty pharmaceutical company’s stock worth $2,708,000 after buying an additional 17,000 shares during the period. Louisiana State Employees Retirement System raised its stake in AMAG Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,000 shares of the specialty pharmaceutical company’s stock worth $316,000 after buying an additional 200 shares during the period. Fox Run Management L.L.C. purchased a new stake in AMAG Pharmaceuticals during the first quarter worth $992,000. Cornerstone Financial Partners LLC raised its stake in AMAG Pharmaceuticals by 306.3% in the first quarter. Cornerstone Financial Partners LLC now owns 49,492 shares of the specialty pharmaceutical company’s stock worth $1,116,000 after buying an additional 37,312 shares during the period. Finally, Bank of Montreal Can raised its stake in AMAG Pharmaceuticals by 4,071.4% in the first quarter. Bank of Montreal Can now owns 66,492 shares of the specialty pharmaceutical company’s stock worth $1,500,000 after buying an additional 64,898 shares during the period.

Several research analysts have recently commented on AMAG shares. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Jefferies Group LLC set a $40.00 price objective on AMAG Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, March 18th. ValuEngine downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Barclays PLC reiterated a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a report on Monday, May 15th. Finally, Citigroup Inc. decreased their price objective on AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a report on Friday, July 7th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $28.09.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.